Cary Carpenter, MD
Family Medicine · Choctaw, OKNPI 1053311548
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AstraZeneca at 27.8% of the total.
Across 176 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$765
- Novo Nordisk$336
- AbbVie$294
- Lilly USA, LLC$158
- Amgen$151
- GSK$143
- plus $904 from 24 others
Across 4 payments — averaging $13,961 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$41K
- Merck$15K
What the payments were for
- Food & beverage$2,73299%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $765 |
| Novo Nordisk | 20 | $336 |
| AbbVie(2 entities) | 25 | $294 |
| Lilly USA, LLC | 9 | $158 |
| Amgen | 8 | $151 |
| GSK | 10 | $143 |
| Bayer | 6 | $111 |
| Exact Sciences | 6 | $106 |
| Johnson & Johnson | 6 | $97 |
| Pfizer | 6 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $79 |
| Supernus Pharmaceuticals, Inc. | 3 | $51 |
| Merck | 3 | $40 |
| Dexcom, Inc. | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $30 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Corium, LLC | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Shire North American Group Inc | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Dermira, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Antares Pharma, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Adlon Therapeutics L.p. | 1 | $11 |
How this compares
$2,750 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $82,195 |
| MounjaroTirzepatide | 17 | $40,202 |
| EliquisApixaban | 50 | $38,619 |
| FarxigaDapagliflozin Propanediol | 57 | $35,072 |
| JardianceEmpagliflozin | 36 | $32,715 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $23,553 |
| TrulicityDulaglutide | 21 | $19,949 |
| ElmironPentosan Polysulfate Sodium | 12 | $11,653 |
| JanuviaSitagliptin Phosphate | 15 | $11,477 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $8,173 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $4,486 |
| Liothyronine Sodium | 109 | $3,559 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $2,987 |
| Omeprazole | 133 | $2,320 |
| Insulin Aspart Prot Mix 70-30Insulin Aspart Prot/Insuln Asp | 18 | $2,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $336 | $82,19580 claims |
| Lilly USA, LLCMounjaro, Trulicity | $158 | $60,15138 claims |
| AstraZenecaFarxiga, Symbicort | $765 | $43,24575 claims |
| PfizerEliquis | $93 | $38,61950 claims |
| GSKTrelegy Ellipta | $143 | $23,55335 claims |
| MerckJanuvia | $40 | $11,47715 claims |
| AbbVieSynthroid, Armour Thyroid | $294 | $2,70035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Choctaw
- Alexander FrankOklahoma City$3.1M
- Stanley ShadidEdmond$363K
- Geoffrey PlumleeTulsa$297K
- Curtis HarrisAda$125K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Lisa ConneryNorman$105K
- Michael RobinsonElk City$84K
- Kimberly HuttonTulsa$76K
- James BeebeMuskogee$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.